DK1715890T3 - CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropati - Google Patents
CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropatiInfo
- Publication number
- DK1715890T3 DK1715890T3 DK05713358T DK05713358T DK1715890T3 DK 1715890 T3 DK1715890 T3 DK 1715890T3 DK 05713358 T DK05713358 T DK 05713358T DK 05713358 T DK05713358 T DK 05713358T DK 1715890 T3 DK1715890 T3 DK 1715890T3
- Authority
- DK
- Denmark
- Prior art keywords
- diabetic nephropathy
- microalbuminuria
- ctgf
- therapy
- patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54412104P | 2004-02-11 | 2004-02-11 | |
| US56101804P | 2004-04-08 | 2004-04-08 | |
| US57840104P | 2004-06-09 | 2004-06-09 | |
| US62080204P | 2004-10-20 | 2004-10-20 | |
| PCT/US2005/004367 WO2005077413A1 (en) | 2004-02-11 | 2005-02-11 | Ctgf as target for the therapy of diabetic nephropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1715890T3 true DK1715890T3 (da) | 2008-11-17 |
Family
ID=34865408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05713358T DK1715890T3 (da) | 2004-02-11 | 2005-02-11 | CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropati |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20050214294A1 (da) |
| EP (2) | EP1977762A1 (da) |
| CN (1) | CN101884789A (da) |
| AT (1) | ATE400297T1 (da) |
| AU (1) | AU2005212371B2 (da) |
| CA (1) | CA2555789A1 (da) |
| DE (1) | DE602005008013D1 (da) |
| DK (1) | DK1715890T3 (da) |
| ES (1) | ES2311973T3 (da) |
| HK (1) | HK1095762A1 (da) |
| IL (1) | IL177437A (da) |
| NZ (1) | NZ549784A (da) |
| PL (1) | PL1715890T3 (da) |
| PT (1) | PT1715890E (da) |
| WO (1) | WO2005077413A1 (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1326361A (zh) * | 1998-09-08 | 2001-12-12 | 亨利福特保健系统公司 | 通过修饰、调节及抑制结缔组织生长因子来检查、预防和治疗肾脏疾病的方法 |
| US20060281668A1 (en) | 2005-05-05 | 2006-12-14 | Fibrogen, Inc. | Vascular disease therapies |
| ES2352801T3 (es) * | 2005-12-22 | 2011-02-23 | Kiacta Sàrl | Tratamiento de nefropatía diabética. |
| MX2009006768A (es) * | 2006-12-22 | 2009-08-31 | Bellus Health Int Ltd | Metodos, compuestos, y composiciones para tratar trastornos metabolicos y diabetes. |
| US20090054473A1 (en) * | 2007-08-22 | 2009-02-26 | Gilead Colorado, Inc. | Therapy for complications of diabetes |
| US8946172B2 (en) | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
| DK2331141T3 (da) | 2008-08-25 | 2016-04-04 | Excaliard Pharmaceuticals Inc | Antisense-oligonukleotider, som er rettet mod bindevævsvækstfaktor, og anvendelser deraf |
| TWI593416B (zh) | 2011-02-02 | 2017-08-01 | 艾克厘德製藥公司 | 利用針對結締組織生長因子（ｃｔｇｆ）目標之反義化合物治療瘢痕或肥厚性疤痕之方法 |
| RU2718054C2 (ru) * | 2013-11-28 | 2020-03-30 | СиЭсЭл ЛИМИТЕД | Способ лечения нефропатии |
| CA3072427C (en) | 2017-08-08 | 2023-12-05 | Fresenius Medical Care Holdings, Inc. | Systems and methods for treating and estimating progression of chronic kidney disease |
| EP3831392A4 (en) * | 2018-07-31 | 2022-08-17 | Lemonex Inc. | COMPOSITION FOR INHIBITING CTGF EXPRESSION |
| CN109402127B (zh) * | 2018-09-29 | 2021-12-10 | 复旦大学附属眼耳鼻喉科医院 | 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用 |
| CN109453191A (zh) * | 2018-12-06 | 2019-03-12 | 郑州大学第附属医院 | GSK-3β抑制剂及在糖尿病肾病干预新靶点的应用 |
| US20220324953A1 (en) * | 2019-06-04 | 2022-10-13 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-connective tissue growth factor antibody and application thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770209A (en) | 1991-08-30 | 1998-06-23 | University Of South Florida | Acceleration of wound healing using connective tissue growth factor |
| US5408040A (en) * | 1991-08-30 | 1995-04-18 | University Of South Florida | Connective tissue growth factor(CTGF) |
| US5876730A (en) | 1997-08-07 | 1999-03-02 | Childrens Hospital Research Foundation | Heparin-binding growth factor (HBGF) polypeptides |
| AU1682699A (en) * | 1997-12-25 | 1999-07-19 | Japan Tobacco Inc. | Monoclonal antibody against connective tissue growth factor and medicinal uses thereof |
| WO2000002450A1 (en) | 1998-07-08 | 2000-01-20 | Fibrogen, Inc. | Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives |
| CN1326361A (zh) | 1998-09-08 | 2001-12-12 | 亨利福特保健系统公司 | 通过修饰、调节及抑制结缔组织生长因子来检查、预防和治疗肾脏疾病的方法 |
| US6348329B1 (en) * | 1998-11-06 | 2002-02-19 | Fibrogen, Inc. | Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use |
| CA2350182A1 (en) | 1998-11-06 | 2000-05-18 | Fibrogen, Inc. | Connective tissue growth factor (ctgf) and methods of use |
| AU775391B2 (en) * | 1998-12-14 | 2004-07-29 | Fibrogen, Inc. | Connective tissue growth factor fragments and methods and uses thereof |
| US6706491B1 (en) | 1999-04-09 | 2004-03-16 | The Board Of Trustees Of The University Of Illinois | Reagents and methods for identifying and modulating expression of genes regulated by p21 |
| US6965025B2 (en) * | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
| EP1463531B1 (en) | 2001-12-11 | 2011-09-28 | Fibrogen, Inc. | Methods for inhibiting ocular processes |
| AU2003221762B2 (en) | 2002-04-30 | 2008-09-25 | Alcon, Inc. | Agents which regulate, inhibit or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
| US7405274B2 (en) | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
| US8258105B2 (en) | 2003-10-07 | 2012-09-04 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides optimized for kidney targeting |
-
2005
- 2005-02-11 US US11/057,323 patent/US20050214294A1/en not_active Abandoned
- 2005-02-11 AT AT05713358T patent/ATE400297T1/de active
- 2005-02-11 PL PL05713358T patent/PL1715890T3/pl unknown
- 2005-02-11 EP EP08011905A patent/EP1977762A1/en not_active Withdrawn
- 2005-02-11 EP EP05713358A patent/EP1715890B1/en active Active
- 2005-02-11 CA CA002555789A patent/CA2555789A1/en not_active Abandoned
- 2005-02-11 AU AU2005212371A patent/AU2005212371B2/en not_active Ceased
- 2005-02-11 NZ NZ549784A patent/NZ549784A/en unknown
- 2005-02-11 ES ES05713358T patent/ES2311973T3/es active Active
- 2005-02-11 PT PT05713358T patent/PT1715890E/pt unknown
- 2005-02-11 DE DE602005008013T patent/DE602005008013D1/de active Active
- 2005-02-11 CN CN2010102312546A patent/CN101884789A/zh active Pending
- 2005-02-11 WO PCT/US2005/004367 patent/WO2005077413A1/en active Application Filing
- 2005-02-11 DK DK05713358T patent/DK1715890T3/da active
-
2006
- 2006-08-10 IL IL177437A patent/IL177437A/en active IP Right Grant
-
2007
- 2007-03-29 HK HK07103389A patent/HK1095762A1/xx unknown
-
2010
- 2010-06-03 US US12/802,373 patent/US8314059B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL1715890T3 (pl) | 2009-01-30 |
| CA2555789A1 (en) | 2005-08-25 |
| EP1977762A1 (en) | 2008-10-08 |
| WO2005077413A1 (en) | 2005-08-25 |
| AU2005212371A1 (en) | 2005-08-25 |
| EP1715890B1 (en) | 2008-07-09 |
| AU2005212371B2 (en) | 2010-05-13 |
| US20100291098A1 (en) | 2010-11-18 |
| PT1715890E (pt) | 2008-10-17 |
| HK1095762A1 (en) | 2007-05-18 |
| EP1715890A1 (en) | 2006-11-02 |
| ES2311973T3 (es) | 2009-02-16 |
| DE602005008013D1 (de) | 2008-08-21 |
| ATE400297T1 (de) | 2008-07-15 |
| CN101884789A (zh) | 2010-11-17 |
| NZ549784A (en) | 2008-06-30 |
| IL177437A0 (en) | 2006-12-10 |
| IL177437A (en) | 2013-06-27 |
| US20050214294A1 (en) | 2005-09-29 |
| US8314059B2 (en) | 2012-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1715890T3 (da) | CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropati | |
| BR0308928A (pt) | Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular | |
| CY2016015I2 (el) | Αζετιδινες ως αναστολεις μεκ για τη θεραπευτικη αγωγη πολλαπλασιαστικων ασθενειων | |
| ATE446102T1 (de) | Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii | |
| EA201100335A1 (ru) | Производные пурина для применения при лечении связанных с fab заболеваний | |
| UY32030A (es) | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" | |
| CY1110889T1 (el) | C-αρυλο γλυκοζιτικοι sglt2 αναστολεις και μεθοδος για την παραγωγη τους | |
| NO20083002L (no) | Fremgangsmate for anvendelse av CD40-bindende forbindelser | |
| ATE542823T1 (de) | 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen | |
| EA200700407A1 (ru) | Производные хиназолина и их использования при лечении тромбоцитемии | |
| EA200901211A1 (ru) | Антигены белка с5 и их применение | |
| EA201000914A1 (ru) | Новые терапевтические подходы в лечении смт и связанных с ней расстройств | |
| EP1958648A4 (en) | THERAPEUTIC PROCESS FOR BLOOD CLEANING DISORDER | |
| DK1889920T3 (da) | In vitro fremgangsmåde atil identifikation af forbindelse atil cancerterapi | |
| ATE510536T1 (de) | Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen | |
| ITRM20050179A1 (it) | Composizione impiegabile per il trattamento delle patologie paradontali. | |
| CY1110620T1 (el) | Μεθοδος θεραπειας οξειας παραρρινοκολπιτιδας | |
| EA200700406A1 (ru) | Производные хиназолина , применяемые для лечения поражений периферических артерий и в качестве ингибиторов фосфодиэстеразы | |
| BR0313588A (pt) | Métodos para o tratamento da demência com base em apo e genótipo | |
| EP1768656A4 (en) | TREATMENT OF OCULAR DISEASES | |
| ATE557102T1 (de) | Methoden zur vorhersage der wirksamkeit von interferon therapie bei multiple sklerose patienten und methoden zur diagnose der krankheit | |
| DK1596879T3 (da) | Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis | |
| DE602008004556D1 (de) | Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin | |
| EP1768660A4 (en) | COMPOUNDS AND METHODS FOR TREATING DIABETIC VASCULAR DISEASES | |
| WO2006076119A3 (en) | Treatment of skin diseases |